 Home > Active Ingredient News > Blood System > Leuk Lymphoma: Association of elevated creatine kinase with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.

Leuk Lymphoma: Association of elevated creatine kinase with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.

 Last Update: 2022-04-24
 Source: Internet
 Author: User

Tags

1 1a 8

all bran nutrition

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Elevated creatine kinase (CK) is a common complication of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) and is associated with key treatment outcomes (overall survival (OS) and event-free survival (EFS) )) is still unknown
.

Figure 1: Flowchart

In a single-center retrospective study of 283 patients with chronic CML (median follow-up, 8.
8 years), 71.
7% developed hyperckemia, imatinib and second-generation There was no difference in the incidence of TKIs (SG-TKIs)
.

Figure 2: Cumulative incidence of elevated CK in patients with chronic myeloid leukemia (n283)
.

(A) Cumulative incidence of elevated creatine kinase (CK), defined as any value above baseline and as TKI-like, in 283 chronic myeloid leukemia patients stratified by type of tyrosine kinase inhibitor continued to rise for 6 months

Figure 2: Cumulative incidence of elevated CK in patients with chronic myeloid leukemia (n283)

In multivariate Cox regression analysis, hyperckemia was associated with better OS, while moderate and high Sokal risk scores were associated with poorer OS

Figure 3: Overall survival in patients with chronic myeloid leukemia (n¼ 283)
.

(A) Overall survival data from diagnosis in 283 chronic myeloid leukemia patients according to elevated creatine kinase (CK)

Figure 3: Overall survival in patients with chronic myeloid leukemia (n¼ 283)

Figure 4: Event-free survival in patients with chronic myeloid leukemia (n¼283)
.

(A) Event-free survival data from diagnosis in 283 chronic myeloid leukemia patients based on elevated creatine kinase (CK)

Figure 4: Event-free survival in patients with chronic myeloid leukemia (n¼283)

The research team believes that further studies are needed to determine whether patients reduce TKI doses or discontinue treatment because of the presence of high CK, and whether these patients are advised to avoid exhausting physical activity and avoid statin use as much as possible, regardless of whether these factors increase.

In conclusion, this study provides evidence for the prognostic value of TKI therapy in CML patients

Original source:

Bankar A, Lipton JH.

Bankar A, Lipton JH.
Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.
Leuk Lymphoma.
2022 Jan;63(1):179-188.
doi: 10.
1080/10428194.
2021.
1971219.
Epub 2021 Sep 8.
PMID: 34493150.
Bankar A, Lipton JH.
Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.
Leuk Lymphoma.
2022 Jan;63(1):179-188.
doi: 10.
1080/10428194.
2021 .
1971219.
Epub 2021 Sep 8.
PMID: 34493150.
Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.